An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
26 participants
Jul 24, 2025
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Pembrolizumab 200mg will be administered via intravenous infusion over 30 minutes, twice at 21-day intervals.
Docetaxel 50 mg/m2 will be administered over 60 minutes.
Oxaliplatin 85 mg/m2 will be administered over 2 hours.
Leucovorin 200 mg/m2 will be administered over 2 hours.
5-FU 2600 mg/m2 will be administered over 24 hours.
25Gy (5Gy×5fr)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07018570